GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.
Considerable on MSN
GSK buys Rapt in $2.2B deal
GSK agreed to acquire Rapt Therapeutics for $2.2 billion on Tuesday, a move that ...
GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...
GlobalData on MSN
GSK acquires RAPT Therapeutics for $2.2bn
The acquisition will strengthen GSK’s immunology pipeline, which is a key area of focus for the pharma company.
GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...
GSK has agreed to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing novel ...
GSK to acquire California-based biopharma company, RAPT Therapeutics for $2.2 billion: London, UK Tuesday, January 20, 2026, 16:45 Hrs [IST] GSK plc announced that it has entered ...
South Korean biotech Alteogen (Kosdaq: 196170) has signed an exclusive license agreement with Tesaro, a unit of GSK (LSE: GSK ...
GlobalData on MSN
JPM26: GSK banks on recent AI deals to offset patent expiries
GSK noted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.
CAMP4 Therapeutics Corporation (NASDAQ: CAMP) on Thursday entered into a strategic research, collaboration, and license agreement with GSK Plc (NYSE: GSK). The collaboration aims to identify and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results